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Abstract
Background: The Gly482Ser polymorphism in peroxisome proliferator-activated receptor
gamma coactivator-1 alpha (PPARGC1A) has been demonstrated to be associated with diabetes,
obesity and hypertension, all of which are important risk factors for left ventricular diastolic
dysfunction.
Methods: The PPARGC1A Gly482Ser polymorphism was genotyped in a community-based cohort
of 499 men and 533 women, who also underwent an echocardiographic examination to determine
their left ventricular diastolic function. The association between the polymorphism and the
presence of diastolic dysfunction was evaluated using logistic regression models.
Results: The Ser allele of the PPARGC1A Gly482Ser polymorphism was significantly associated with
a lower risk of diastolic dysfunction in men, but not in women. In a model adjusting for potential
confounders (age, body mass index, leisure time physical activity, hypertension and diabetes) the
results were still significant and substantial (odds ratio 0.13, 95% confidence interval 0.03–0.54, p
for trend = 0.004). The results were consistent in a series of models, and they imply a multiplicative,
protective effect of the Ser allele, with lower risk of diastolic dysfunction for each copy of the allele.
Conclusion: The Ser allele of the PPARGC1A Gly482Ser polymorphism was associated with
decreased risk of diastolic left ventricular dysfunction in men, but not in women, in our large
community-based sample. It was associated with a substantially decreased risk, even after
adjustment for potential confounders. The clinical importance of the findings has to be established
in further studies.
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Heart failure is one of the most common, costly, disabling
and deadly diseases, with a lifetime risk of about 20% for
a person aged 40 years [1]. Left ventricular systolic func-
tion is normal in about half of all heart failure patients [2-
4], a condition often referred to as diastolic heart failure.
No universally accepted measurement defining left ven-
tricular diastolic dysfunction exists but Doppler-derived
diastolic filling indexes have been used extensively [5-7].
Hypertension, diabetes and obesity are more important
risk factors in patients with diastolic heart failure, as com-
pared to heart failure patients with reduced left ventricular
systolic function [3,4,8,9].
Peroxisome proliferator-activated receptor gamma coacti-
vator-1 alpha (PPARGC1A, often referred to as PGC1α) is
a major regulator of adipocyte, skeletal muscle and liver
metabolism [10]. A frequent substitution of a glycine to
serine amino acid at residue 482 in human PPARGC1A
was described in 2001 [11], and has been demonstrated to
be associated with diabetes [11-14], hypertension [15-
17], and obesity [18,19]. Further, there are animal data to
support a direct role for PPARGC1A in the development of
heart failure [20-22].
We hypothesized that the PPARGC1A Gly482Ser
(rs8192673) polymorphism would be associated with
diastolic dysfunction measured by Doppler-derived
diastolic filling indexes. Further, we aimed to examine
whether this association was independent of potential




Within the framework of the Skaraborg Project this study
includes data from a surveillance of the population in
Vara, a small community in a rural area in South-western
of Sweden [18,23]. Residents in Vara were randomly
selected from the population census register stratified by
sex and 5-years age-groups between 30 and 74 years. Indi-
viduals below age 50 were over-sampled three times as
compared to those who were older. Participation was
based on conducting a study visit to the nurse for a phys-
ical examination, returning blood samples, and filling in
the questionnaires. Between 2001 and 2003, 1811 unre-
lated participants were accordingly included (participa-
tion rate 82%).
These participants were then consecutively invited to a
separate visit for an echocardiografic examination of the
heart (UCG) and in all 1058 subjects, 515 men and 543
women were successfully examined. The presence or
absence of diastolic dysfunction could be determined for
1044 participants (91% of all who were invited to the
UCG investigation). The genotyping of the PGC1a poly-
morphism failed in six subjects, another six had anamne-
ses of heart failure while 1032 subjects (499 men and 533
women) remained for the present study.
The research ethical committee in Gothenburg approved
the study. A written informed consent was collected both
at the baseline examination and before they underwent
the UCG.
Assessment of clinical variables
Known doctors' diagnoses of diabetes, hypertension,
hyperlipidemia, angina pectoris, atrial fibrillation and
information on past events of hospitalization were col-
lected by the nurses according to standardised forms.
Information concerning demography, socio-economy,
and lifestyles including physical activity at leisure time
and smoking was collected by questionnaires. Leisure
time physical activity (LTPA) was divided into four differ-
ent categories, ranging from sedentary to hard exercise.
Those who participated in regular physical activity for at
least 2 hours a week were considered to be physically
active in leisure time (levels 3 and 4), while the others
were considered sedentary (levels 1 and 2). The question-
naires were filled out at the clinic and the nurses gave
some assistance when needed.
A standard physical examination by the study nurses
included blood pressure readings in a supine position
after 5 minutes rest with the arm at heart level to the near-
est 2 mm Hg. Blood pressure was always measured twice
one minute apart and the mean was used for diagnoses. A
diagnosis of hypertension was based on ongoing blood
pressure lowering medication for hypertension, or
repeated blood pressure levels ≥ 140/90 mm Hg (one or
both) [24,25]. Weight (to the closest 0.1 kg) and height
(to the closest cm) was measured in light clothes and no
shoes. Obesity was characterized by body mass index
(BMI) calculated as body weight in kilo divided by the
square of the height in meters (kg/m2). Obesity was
defined as BMI ≥ 30.0 kg/m2. Waist and hip circumfer-
ences were measured to the closest cm and waist to hip
ratio (WHR) was calculated.
Fasting blood samples were drawn in the morning after a
10-hour overnight fast by the lab technician before a
standard 75-g oral glucose tolerance test (OGTT) was
administered and samples were drawn before the glucose
load and after 2 hours [26]. In subjects without a known
history of diabetes, a second fasting plasma glucose sam-
ple was drawn another day within the next weeks. For this
paper, plasma glucose was analysed in fasting and 2 hours
after the administration of the 75-g glucose load. Diagno-
sis of diabetes was confirmed if there was a known history
of physician diagnosis, and in new cases when the fastingPage 2 of 9
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when the 2 hour plasma glucose value in the OGTT was ≥
11.1 mmol/L [27]. Serum cholesterol was analysed on
fasting samples (standard commercial kits). Hypercholes-
terolemia was defined as serum cholesterol ≥ 6.5 mmol L-
1.
Echocardiographic methods
All participants were examined with echocardiography by
the same senior cardiologist (MS) using a General
Electrics VingMed S 5 System operating with a 3.5 MHz-
probe. Measurements for left ventricular calculations were
taken from Guidelines of the American Society of
Echocardiography [28]. A 2-dimensional echocardiogram
was formed from the left parasternal and apical windows
for measurements. The ejection fraction was calculated
from apical 4- and 2-chamber views with longitudinal
systolic shortening mean index/atrioventricular plane dis-
placement technique in addition to semi-quantitative vis-
ual estimation method [29,30]. The ventricular diastolic
function was based on several parameters (see below) and
their respective normal ranges were defined for different
age categories [31].
The early and late diastolic velocities and the ratios of
these were determined by a pulsed wave Doppler signal at
the tips of the mitral valve in the apical 4-chamber view.
The E-wave peak (early filling) to A-wave peak (atrial fill-
ing), and the ratio was determined. The isovolumetric
relaxation time (IVRT), from the closure of the AV-valve to
the opening of the mitral valve was also measured. To
indirectly measure the distensibility in the left ventricle
the deceleration time (DT), the peak E to baseline slope
was measured. Tissue Velocity Imaging (TVI) was used in
both septum and in the more stable lateral wall to detect
pseudo normalization. The patient was also told to do val-
salva during the registration.
Diastolic dysfunction was considered when evidence of
abnormal left ventricular diastolic relaxation, filling, and
diastolic distensibility and diastolic stiffness was found in
the presence of normal or mildly reduced left ventricular
systolic function (left ventricular systolic ejection fraction
(LVEF ≥ 45%) according to recommendations from ESC
[32]. For this study, diastolic function was dichotomised
as being normal or not.
DNA extraction and genotyping
As previously published, [18] DNA was extracted from
whole blood using QiaGen MiniPrep (QiaGen, Germany)
at the DNA/RNA Genotyping Lab, SWEGENE Resource
Center for Profiling Polygenic Disease, Lund University,
Malmö University Hospital, Malmö, Sweden. The
PPARGC1A Gly482Ser polymorphism (rs8192673) was
genotyped using an allelic discrimination assay (assay on
demand) performed with an ABI 7900 system (Applied
Biosystems Inc., USA) using the PCR primers; 5'-TGGA-
GAATTGTTCATTACTGAAATCACTGT-3' (forward) and 5'-
GGTCATCCCAGTCAAGCTGTTTT-3' (reverse) and Taq-
Man MGB probes, Fam-5'-CTATTGACGCAGAAAG-3' and
Vic-5'-CTCCTATTGACCCAGAAAG-3'. Genotyping effi-
ciency was 99.8%, and 100% genotyping accuracy was
shown when 5% of the samples were re-run. The fre-
quency distribution was in agreement with the Hardy-
Weinberg expectations in men and women, jointly and
separately (P > 0.97 for all).
Statistical methods
Statistical analysis was performed using SPSS 14.0 for PC.
Standard methods were used for descriptive statistics.
Analyses were stratified on sex according to our a priori
analysis plan based on the hypothesis that the association
between PPARGC1A Gly482Ser and diastolic dysfunction
could differ by sex. Confounding by age, or by CVD risk
factors, was accounted for by stratification or by multivar-
iate analyses. The rural population in Vara is very homog-
enous [33] and there are thus no population stratification
concerns to address. Prevalence's of the complete study
population were standardised according to the popula-
tion in Vara by 5-year age groups. Association between
diastolic dysfunction and categorical variables were ana-
lyzed by logistic regression and expressed as odds ratios
(OR) with 95% confidence intervals (CI). Differences in
means between groups were analyzed by general linear
models (GLM). All tests were 2-sided and statistical signif-
icance was assumed when p < 0.05.
Statement of responsibility
The authors had full access to the data and take responsi-
bility for its integrity. All authors have read and agree to
the manuscript as written.
Results
Clinical characteristics and PPARGC1A Gly482Ser geno-
type distribution are shown in Table 1. Both women and
men were characterized with a high level of overweight
and a low level of leisure time physical activity. Diastolic
dysfunction was prevalent in 16.5% of the men and
13.0% of the women. The PPARGC1A Gly482Ser geno-
type distributions across different clinical characteristics
by sex are demonstrated in Table 2.
When stratifying the study population by sex, the Ser
allele of the PPARGC1A Gly482Ser polymorphism was
significantly associated with a lower risk of diastolic dys-
function in men, but not in women (Table 3). The effect
was substantial (odds ratio [OR] 0.13–0.19 for Ser/Ser vs.
Gly/Gly), statistically significant and consistent in differ-
ent models including potential confounders (age, body
mass index, leisure time physical activity, hypertensionPage 3 of 9
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we examined whether carriers of at least one copy of the
Ser allele had an increased risk of diastolic dysfunction as
compared to non-carriers (Table 4). In these models, car-
riage of the Ser allele was associated with a decreased risk
of diastolic dysfunction (OR, 0.52; 95% confidence inter-
val 0.29–0.92, p = 0.026 in the fully multivariable-
adjusted model). In women, again there was no signifi-
cant effect of the PPARGC1A Gly482Ser polymorphism.
Although the results were different for men and women,
the interaction between PPARGC1A Gly482Ser and sex
was non-significant upon formal testing (p = 0.19). There
was no significant interaction between PPARGC1A
Gly482Ser and age (p = 0.61) or between PPARGC1A
Gly482Ser and menopausal status (using age 55 in
women as a proxy; p = 0.24). With a significance level of
0.05, we had 87% (men) and 90% (women) power to




In this community-based sample from the general popu-
lation, the PPARGC1A Gly482Ser polymorphism was
associated with the presence of diastolic left ventricular
dysfunction in men, but not in women. More specifically,
the Ser allele was associated with a substantially decreased
risk of diastolic dysfunction, also after adjustment for
Table 1: Descriptive characteristics of the study population
Variables (units) Men N = 499 Women N = 533
Age (years) 50.0(12.2) 50.3(11.9)
Body mass index (kg m-2) 27.0(4.4) 27.1(4.4)
Waist circumference (cm) 95.1(11.6) 85.9(11.6)
Waist-hip ratio 0.95(0.07) 0.84(0.07)
Systolic blood pressure (mm Hg) 127(13.9) 123(13.9)
Diastolic blood pressure (mm Hg) 73(9.5) 70(9.5)
Diastolic dysfunction (%) 79(16.5) 58(13.0)
Hypertension (%) 96(19.3) 96(20.6)
Diabetes (%) 38(8.0) 38(8.1)
Obesity (%) 96(19.3) 127(24.8)
Low leisure-time physical activity (%) 307(62.2) 377(72.0)
PGC1αGly482Ser genotypes:
Gly/Gly (%) 214(42.8) 229(43.2)
Gly/Ser (%) 237(47.6) 243(45.3)
Ser/Ser (%) 48(9.6) 61(11.5)
Data are means (SD) or numbers (%). Means were adjusted for age difference using general linear models (GLM) and proportions were age 
standardized according to the population in Vara.
Table 2: Characteristics of the PGC1α Gly482Ser polymorphism, in males () and females ()
Gly/Gly Gly/Ser Ser/Ser
(N:/N:) (214/229) (237/243) (48/61)
Age (years)  51.3 (12.2) 50.7(12.2) 50.8 (12.2)
 51.8 (11.8) 49.4 (11.8) 47.9 (11.8)
Body mass index (kg m-2)  26.9 (3.4) 27.2 (3.4) 27.2 (3.5)
 26.8 (5.1) 27.4 (5.1) 27.0 (5.1)
Low leisure-time  125 (59.1) 150 (63.1) 32 (63.3)
physical activity (%)  163 (71.0) 173 (72.8) 41 (72.9)
Systolic blood pressure  128 (14.2) 127 (14.2) 125 (14.2)
(mmHg)  123 (13.4) 121 (13.4) 124 (13.4)
Diastolic blood pressure  74 (9.6) 73 (9.6) 73 (9.6)
(mmHg)  70 (9.4) 69 (9.4) 70 (9.3)
Diastolic dysfunction (%)  42(19.9) 34 (15.5) 3 (5.1)
 29 (11.7) 27 (15.7) 2 (6.0)
Hypertension (%)  44 (21.1) 43 (18.8) 9 (13.7)
 51 (22.2) 33 (17.7) 12 (25.2)
Diabetes (%)  15 (7.4) 19 (9.1) 4 (4.7)
 18 (7.9) 14 (7.2) 6 (9.0)
Data are means (standard deviations).Page 4 of 9
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sure time physical activity, hypertension and diabetes. The
results were consistent in a series of models, and they
imply a multiplicative, protective effect of the Ser allele,
with lower risk of diastolic dysfunction for each copy of
the allele. In the present study, the prevalence of diastolic
dysfunction was somewhat higher in men than in women.
Left ventricular systolic function is more commonly pre-
served in women with heart failure [2,3], but the preva-
lence of diastolic dysfunction in the general population
has been established to be higher in men than women [9].
Comparisons with Previous Studies
Recently, other PPARGC1A polymorphisms were shown
to be associated with presence of self-reported cardiovas-
cular disease, and it was suggested that this association
was mediated via DNA damage [34]. Also, the PPARGC1A
Gly482Ser polymorphism has been associated with
hypertrophic cardiomyopathy [35]. Further, previous
studies have demonstrated the Ser allele of the PPARGC1A
Gly482Ser to be associated with an increased risk of dia-
betes [11-13], but a recent meta-analysis have implied
only a modest role for the polymorphism in the develop-
ment of diabetes [14]. Moreover, the Ser allele has been
associated with obesity in some studies [18,19], whereas
other have failed to find significant associations between
the PPARGC1A Gly482Ser polymorphism and various
body fat measures and the metabolic syndrome in differ-
ent study populations [36-38]. The PPARGC1A Gly482Ser
polymorphism has also been associated with hyperten-
sion in previous studies [15-17]. In two of these studies,
the Ser allele conferred a lower risk of hypertension
[15,16], whereas one study demonstrated an increased
risk of hypertension for carriers of the Ser allele [17].
However, the latter study consisted only of subjects with
diabetes; hence this inconsistency could be a result of a
gene-environment interaction. A recent large meta-analy-
sis comprising of 13 949 individuals from 17 studies, of
which 6 042 were from previously unpublished datasets,
failed to find an association of the PPARGC1A Gly482Ser
polymorphism with hypertension overall. However, they
reported higher systolic and diastolic blood pressure in
younger individuals (< 50 years of age) with the Ser allele,
whereas there were no such associations in elderly [39].
To the best of our knowledge, this is the first epidemiolog-
ical study of associations between the PPARGC1A
Gly482Ser polymorphism and diastolic dysfunction. We
observed a protective effect of the Ser allele, with lower
risk of diastolic dysfunction for each copy of the allele in
men. This contrasts with prior findings that the Ser allele
is associated with higher risk of diabetes, [11-13], but
agrees with findings that it is associated with lower risk of
hypertension, [15,16] both of which are major risk factors
Table 3: Associations between the PGC1α Gly482Ser polymorphism and diastolic dysfunction, in males and females.
Gly/Gly Gly/Ser Ser/Ser P for trend
Males N = 214 N = 237 N = 48
Covariates OR OR (95% CI) OR (95%CI)
Age 1.0 0.70 (0.40 – 1.22) 0.19 (0.05 – 0.72) 0.012
Age, body mass index 1.0 0.64 (0.36 – 1.14) 0.15 (0.04 – 0.61) 0.005
Age, low leisure-time physical activity 1.0 0.72 (0.41 – 1.26) 0.19 (0.05 – 0.72) 0.015
Age, body mass index, low leisure-time physical activity 1.0 0.66 (0.37 – 1.17) 0.16 (0.04 – 0.66) 0.007
Age, hypertension 1.0 0.70 (0.40 – 1.22) 0.19 (0.05 – 0.72) 0.012
Age, diabetes 1.0 0.67 (0.38 – 1.19) 0.16 (0.04 – 0.63) 0.007
Age, hypertension, diabetes 1.0 0.68 (0.38 – 1.20) 0.14 (0.04 – 0.58) 0.007
Age, body mass index, low leisure-time physical activity, hypertension, 
diabetes
1.0 0.62 (0.34 – 1.13) 0.13 (0.03 – 0.54) 0.004
Gly/Gly Gly/Ser Ser/Ser P for trend
Females N = 229 N = 243 N = 61
Covariates OR OR (95% CI) OR (95%CI)
Age 1.0 1.31 (0.68 – 2.55) 0.30 (0.06 – 1.45) 0.533
Age, BMI 1.0 1.22 (0.61 – 2.41) 0.33 (0.07 – 1.60) 0.495
Age, low leisure-time physical activity 1.0 1.39 (0.71 – 2.73) 0.31 (0.06 – 1.49) 0.603
Age, body mass index, low leisure-time physical activity 1.0 1.29 (0.64 – 2.58) 0.33 (0.07 – 1.62) 0.550
Age, hypertension 1.0 1.31 (0.67 – 2.53) 0.30 (0.06 – 1.47) 0.529
Age, diabetes 1.0 1.38 (0.70 – 2.72) 0.33 (0.07 – 1.60) 0.622
Age, hypertension, diabetes 1.0 1.68 (0.82 – 3.44) 0.32 (0.06 – 1.59) 0.777
Age, body mass index, low leisure-time physical activity, hypertension, 
diabetes
1.0 1.60 (0.77 – 3.35) 0.35 (0.07 – 1.69) 0.740
Data presented as odds ratios (OR) with 95% confidence interval (CI).Page 5 of 9
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ings were independent of the presence of hypertension
and diabetes. Further studies are needed to confirm our
results and to further elucidate the role of PPARGC1A in
the development of diastolic dysfunction.
Possible Mechanisms
PPARGC1A is a key metabolic protein, which induces and
coordinates gene expression of metabolic genes through
specific interaction with transcription factors that bind to
the promoter regions the genes. It stimulates mitochon-
drial biogenesis and is a major regulator of adipocyte,
skeletal muscle and liver glucogenesis metabolism [10].
It is plausible that PPARGC1A levels and PPARGC1A gene
polymorphisms could be associated with cardiac func-
tion, as PPARGC1A is an important regulator of metabolic
pathways, and as heart failure and diastolic dysfunction
can be caused by metabolic disturbances, such as diabetes
and insulin resistance [40-42], obesity [8,9] and hyperten-
sion [1]. Thus, the association between PPARGC1A and
diastolic dysfunction might be secondary, through these
intermediate phenotypes. However, as the association
between the polymorphism and diastolic dysfunction was
evident also after adjustment for these potential con-
founders, our results imply a more direct effect of
PPARGC1A on the cardiac function. The Ser allele of the
PPARGC1A Gly482Ser polymorphism has been demon-
strated to be associated to lower PPARGC1A mRNA
expression [43]. This could be a potential explanation of
our findings of a protective effect of the Ser allele on
diastolic dysfunction, as animal studies have indicated
high PPARGC1A levels to be involved in the development
of cardiac dysfunction. Forced expression of PPARGC1A
has been demonstrated to activate mitochondrial biogen-
esis and metabolism in cardiac myocytes in vitro, and car-
diac-specific over-expression of PPARGC1A in transgenic
mice has led to mitochondrial proliferation and loss of
sarcomeric structure in cardiac myocytes, leading to a
dilated cardiomyopathy [20].
In the present study, we found associations between the
PPARGC1A Gly482Ser polymorphism and diastolic left
ventricular dysfunction in men, but not in women. The
interaction between PPARGC1A Gly482Ser and sex was
non-significant upon formal testing, which could be due
to low statistical power to detect interactions. However,
the analyses were stratified on sex according to our a priori
analysis plan based on the hypothesis that the association
between PPARGC1A Gly482Ser and diastolic dysfunction
could differ by sex. Previous studies on this polymor-
phism and different metabolic traits have also reported
gender differences [15-19]. There are several possible rea-
sons for this. A recent study demonstrated that the
Table 4: Associations between Ser carriage and the PGC1α Gly482Ser polymorphism and diastolic dysfunction, in males and females.
Gly/Gly Gly/Ser + Ser/Ser P
Males N = 214 N = 285
Diastolic dysfunction, N (%) 42 (19.9) 37 (13.8)
Covariates OR OR (95% CI)
Age 1.0 0.59 (0.34 – 1.02) 0.059
Age, body mass index 1.0 0.54 (0.31 – 0.94) 0.031
Age, low leisure-time physical activity 1.0 0.60 (0.35 – 1.05) 0.073
Age, body mass index, low leisure-time physical activity 1.0 0.55 (0.32 – 0.97) 0.038
Age, hypertension 1.0 0.58 (0.33 – 1.01) 0.054
Age, diabetes 1.0 0.56 (0.32 – 0.98) 0.043
Age, hypertension, diabetes 1.0 0.56 (0.32 – 0.99) 0.044
Age, body mass index, low leisure-time physical activity, hypertension, diabetes 1.0 0.52 (0.29 – 0.92) 0.026
Gly/Gly Gly/Ser+Ser/Ser P
Females N = 229 N = 304
Diastolic dysfunction, N (%) 29 (11.7) 29 (13.6)
Covariates OR OR (95% CI)
Age 1.0 1.08 (0.57 – 2.04) 0.825
Age, body mass index 1.0 1.01 (0.52 – 1.96) 0.968
Age, low leisure-time physical activity 1.0 1.13 (0.59 – 2.16) 0.717
Age, body mass index, low leisure-time physical activity 1.0 1.06 (0.54 – 2.07) 0.867
Age, hypertension 1.0 1.27 (0.64 – 2.50) 0.492
Age, diabetes 1.0 1.13 (0.59 – 2.16) 0.772
Age, hypertension, diabetes 1.0 1.29 (0.65 – 2.56) 0.463
Age, body mass index, low leisure-time physical activity, hypertension, diabetes 1.0 1.24 (0.62 – 2.51) 0.539
Data presented as odds ratios (OR) with 95% confidence interval (CI).Page 6 of 9
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men [43]. Moreover, PPARGC1A interacts with estrogen
receptors and enhances their transcriptional activity [44].
Estrogen receptors are expressed in vascular endothelial
and smooth muscle cells, as well as in myocardial cells,
and there are gender differences in expression [45]. Estro-
gen and estrogen receptors have repeatedly been demon-
strated to be involved in cardiovascular disease and
several recent animal studies have implied a role for estro-
gen receptors in the development of cardiac dysfunction
[46-48]. Also, a recent study of patients with hypertrophic
cardiomyopathy demonstrated polymorphisms in the
estrogen receptor alpha (ESR1) gene, as well as in the
androgen receptor (AR) gene to be associated with left
ventricular wall thickness in men, but not in women [49].
Similarly, another recent study reported a 1.8-fold
increase in estrogen receptor alpha mRNA levels in
patients with end-stage dilated cardiomyopathy [50].
Strengths and limitations
The strengths of this study include the large community-
based population, the high participation rate and well-
characterized cohort. There are also some limitations of
our study. The study has an unknown generalizability to
other ethnic groups. On the other hand, we circumvent
the powerful effects of population stratification. Moreo-
ver, as we only genotyped one polymorphism in the
PPARGC1A gene, there might be other polymorphisms
with an even stronger association to diastolic dysfunction.
Finally, we acknowledge the risk of false positive findings
and the lack of an independent replication sample for our
findings.
Conclusion
In conclusion, the PPARGC1A Gly482Ser polymorphism
was associated with the presence of diastolic left ventricu-
lar dysfunction in men, but not in women, in our large
community-based sample. The Ser allele was associated
with a substantially decreased risk of diastolic dysfunc-
tion, also after adjustment for potential confounders as
age, body mass index, leisure time physical activity, hyper-
tension and diabetes. Since the Ser allele has previously
been associated with decreased expression of PPARGC1A,
it is possible that this is one explanation for the protective
effect observed here. Meanwhile, decreased expression of
PPARGC1A in skeletal muscle has been associated with an
increased risk for type II diabetes. The complexity of the
role of PPARGC1A in cardiovascular disease certainly war-
rants further research and the clinical importance of the
present findings has to be established in further studies.
These potentially hypothesis-generating findings could
stimulate further exploration in other studies.
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